Base de dados : MEDLINE
Pesquisa : D02.455.426.559.847.562.050.200.175.200 [Categoria DeCS]
Referências encontradas : 4840 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 484 ir para página                         

  1 / 4840 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29409738
[Au] Autor:Li XP; Lan JY; Liu DQ; Zhou H; Qian MM; Wang WW; Yang M
[Ad] Endereço:Department of Laboratory Medicine, The Hospital Of Hangzhou Dianzi University, Hangzhou, Zhejiang, China.
[Ti] Título:OCA2 rs4778137 polymorphism predicts survival of breast cancer patients receiving neoadjuvant chemotherapy.
[So] Source:Gene;651:161-165, 2018 Apr 20.
[Is] ISSN:1879-0038
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Genome-wide association study (GWAS) studies have showed that single nucleotide polymorphisms (SNPs) in OCA2 gene were associated with the survival of breast cancer patients treated with adjuvant chemotherapy. To further explain the association between OCA2 SNPs and breast cancer survival, we investigated the predictive value of rs4778137 located in OCA2 in local advanced breast cancer patients receiving neoadjuvant chemotherapy. PATIENTS AND METHODS: A case-cohort with 150 breast cancer patients was performed to evaluate the effects of the OCA2 rs4778137 on breast cancer survival. The association between rs4778137 genotypes and pathological complete response (pCR, defined that the postoperative pathology indicating no residual invasive breast cancer in the breast or the axillary lymph node) were analyzed. Logistic regression analysis was performed to identify the independent predictors of pCR. Survival was assessed by Kaplan-Meier method and Cox regression analysis according to the rs4778137 genotypes. RESULTS: The differences between pCR and the rs4778137 genotypes were statistically significant (p < 0.05). The patients with genotype GG harbored a better disease-free survival (HR: 2.358, p = 0.000) and overall survival (HR: 1.578, p = 0.008) than the patients with genotype CC in rs4778137. The further Univariate and Multivariate survival analysis revealed that SNP rs4778137 was an independent predictive factor of disease-free survival (p = 0.000/p = 0.001) and overall survival (p = 0.006/p = 0.045). CONCLUSION: The OCA2 rs4778137 may be a predictor for the clinical response and survival in local advanced breast cancer patients who received neoadjuvant chemotherapy.
[Mh] Termos MeSH primário: Antineoplásicos/uso terapêutico
Neoplasias da Mama/genética
Neoplasias da Mama/terapia
Proteínas de Membrana Transportadoras/genética
Terapia Neoadjuvante
Polimorfismo de Nucleotídeo Único
[Mh] Termos MeSH secundário: Adulto
Neoplasias da Mama/mortalidade
Quimioterapia Adjuvante
Estudos de Coortes
Terapia Combinada
Epirubicina/uso terapêutico
Feminino
Seguimentos
Seres Humanos
Meia-Idade
Prognóstico
Análise de Sobrevida
Taxoides/uso terapêutico
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Membrane Transport Proteins); 0 (OCA2 protein, human); 0 (Taxoids); 3Z8479ZZ5X (Epirubicin)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180208
[St] Status:MEDLINE


  2 / 4840 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Texto completo
[PMID]:27776843
[Au] Autor:Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
[Ad] Endereço:Institute of Clinical Cancer Research, UCT University Cancer Center, Krankenhaus Nordwest, Frankfurt, Germany. Electronic address: albatran.salah@khnw.de.
[Ti] Título:Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
[So] Source:Lancet Oncol;17(12):1697-1708, 2016 Dec.
[Is] ISSN:1474-5488
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Docetaxel-based chemotherapy is effective in metastatic gastric and gastro-oesophageal junction adenocarcinoma, but has not yet been evaluated in the context of resectable patients. Here we report findings from the phase 2 part of the phase 2/3 FLOT4 trial, which compared histopathological regression in patients treated with a docetaxel-based triplet chemotherapy versus an anthracycline-based triplet chemotherapy before surgical resection. METHODS: In this randomised, open-label, phase 2/3 study, eligible participants were recruited from 28 German oncology centres. Patients with resectable gastric or gastro-oesophageal junction cancer who had clinical stage cT2 or higher, nodal positive (cN+) disease, or both were randomly assigned (1:1) to either three preoperative and three postoperative 3-week cycles of intravenous epirubicin 50 mg/m on day 1, intravenous cisplatin 60 mg/m on day 1, and either fluorouracil 200 mg/m as continuous intravenous infusion or capecitabine 1250 mg/m orally (two doses of 625 mg/m per day) on days 1 to 21 (ECF/ECX group) or four preoperative and four postoperative 2-week cycles of docetaxel 50 mg/m , intravenous oxaliplatin 85 mg/m , intravenous leucovorin 200 mg/m , and fluorouracil 2600 mg/m as a 24 h infusion, all on day 1 (FLOT group). Randomisation was done centrally with an interactive web-response system based on a sequence generated with blocks (block size 2) stratified by Eastern Cooperative Oncology Group performance status, location of primary tumour, age, and nodal status. No masking was done. Central assessment of pathological regression was done according to the Becker criteria. The primary endpoint was pathological complete regression (tumour regression grade TRG1a) and was analysed in the modified intention-to-treat population, defined as all patients who were randomly assigned to treatment excluding patients who had surgery but did not provide resection specimens for central evaluation. The study (including the phase 3 part) has completed enrolment, but follow-up is ongoing and this is an interim analysis. The trial is registered with ClinicalTrials.gov, number NCT01216644. FINDINGS: Between Aug 18, 2010, and Aug 10, 2012, 300 patients (152 patients in the ECF/ECX group; 148 patients in the FLOT group) were enrolled into the phase 2 part of the study, 265 of whom (137 in the ECF/ECX group; 128 in the FLOT group) were assessable on a modified intention-to-treat basis. 119 (93%) of 128 patients in the FLOT group and 126 (92%) of 137 patients in the ECF/ECX group were given all planned preoperative cycles of treatment. FLOT was associated with significantly higher proportions of patients achieving pathological complete regression than was ECF/ECX (20 [16%; 95% CI 10-23] of 128 patients vs eight [6%; 3-11] of 137 patients; p=0·02). 44 (40%) of 111 patients in the ECF/ECX group and 30 (25%) of 119 patients in the FLOT group had at least one serious adverse event involving a perioperative medical or surgical complication. The most common non-surgical grade 3-4 adverse events were neutropenia (52 [38%] of 137 patients in the ECF/ECX group vs 67 [52%] of 128 patients in the FLOT group), leucopenia (28 [20%] vs 36 [28%]), nausea (23 [17%] vs 12 [9%]), infection (16 [12%] vs 15 [12%]), fatigue (19 [14%] vs 11 [9%]), and vomiting (13 [10%] vs four [3%]). INTERPRETATION: Perioperative FLOT was active and feasible to administer, and might represent an option for patients with locally advanced, resectable gastric or gastro-eosophageal junction adenocarcinoma. FUNDING: None.
[Mh] Termos MeSH primário: Adenocarcinoma/tratamento farmacológico
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Neoplasias Esofágicas/tratamento farmacológico
Junção Esofagogástrica
Neoplasias Gástricas/tratamento farmacológico
[Mh] Termos MeSH secundário: Adenocarcinoma/patologia
Adenocarcinoma/cirurgia
Adulto
Idoso
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
Cisplatino/administração & dosagem
Epirubicina/administração & dosagem
Neoplasias Esofágicas/patologia
Neoplasias Esofágicas/cirurgia
Feminino
Seres Humanos
Leucovorina/administração & dosagem
Masculino
Meia-Idade
Terapia Neoadjuvante
Neoplasias Gástricas/patologia
Neoplasias Gástricas/cirurgia
Taxoides/administração & dosagem
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE II; CLINICAL TRIAL, PHASE III; COMPARATIVE STUDY; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Taxoids); 15H5577CQD (docetaxel); 3Z8479ZZ5X (Epirubicin); Q20Q21Q62J (Cisplatin); Q573I9DVLP (Leucovorin)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161026
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE


  3 / 4840 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29374736
[Au] Autor:Sattler T; Bredt C; Surwald S; Rust C; Rieger J; Jakobs T
[Ad] Endereço:Clinic of Diagnostic and Interventional Radiology, Krankenhaus Barmherzige Brueder Muenchen/The Hospital of the Order of St. John of God, Munich, Germany tim.sattler@barmherzige-muenchen.de.
[Ti] Título:Efficacy and Safety of Drug Eluting Bead TACE with Microspheres <150 µm for the Treatment of Hepatocellular Carcinoma.
[So] Source:Anticancer Res;38(2):1025-1032, 2018 02.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIM: To retrospectively evaluate the efficacy and safety of drug eluting bead (DEB) transarterial chemoembolisation (TACE) with microspheres <150 µm for the treatment of hepatocellular carcinoma (HCC) with respect to overall survival, progression-free survival, tumor response and the peri-interventional toxicity. MATERIALS AND METHODS: In this retrospective, single-center study we analyzed 32 HCC-patients (BCLC A: 10 patients, BCLC B: 17 patients, BCLC C: 5 patients), who were treated with (DEB) <15 µm (DCBeadM1®) loaded with epirubicin between 2011 and 2015. We analyzed MRI and CT-scans as well as blood results like AFP, bilirubin and liver enzymes before (t0) and after (t1=first follow-up, t2=last follow-up within 6 months) locoregional treatment. The tumor response was evaluated by MRI and CT considering m-RECIST and the EASL-criteria as well as alpha-fetoprotein (AFP) levels in the peripheral blood. RESULTS: We found a significant tumor response at all follow-up times (p<0.05) according to m-RECIST criteria and a significant tumor response between t0 vs. t1 (p<0.05) and t0 vs. t2 (p<0.05) according to EASL criteria. We observed a significant decrease of the AFP-level between t0 and t1. The objective response rates (ORR) of target lesions were 64.3% and 78.5 % corresponding to m-RECIST and EASL, respectively. The median overall survival (OS) was 30.5 months, the progression-free survival in relation to the target lesion was 14.3 months by using m-RECIST and EASL criteria. In the period of 30 days after treatment we found no grade 5 adverse events (AE). During the follow-up period 1 abscess (3.7%) was observed. In a total of 5 patients, 4 (14.7%) biliomas with no need of treatment and 3 (10.7%) widening of the intrahepatic bile ducts were noted. CONCLUSION: The use of DEB <150 µm (DCBeadM1®) shows promising results in the treatment of HCC without showing substantial hepatic toxicity, but some widening of the intrahepatic bile ducts and one abscess. Further trials are necessary to evaluate the efficacy and toxicity of DEB-TACE with M1®-beads.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Carcinoma Hepatocelular/terapia
Quimioembolização Terapêutica
Sistemas de Liberação de Medicamentos
Neoplasias Hepáticas/terapia
Microesferas
[Mh] Termos MeSH secundário: Carcinoma Hepatocelular/patologia
Doxorrubicina/administração & dosagem
Epirubicina/administração & dosagem
Feminino
Seguimentos
Seres Humanos
Neoplasias Hepáticas/patologia
Masculino
Prognóstico
Estudos Retrospectivos
Segurança
Taxa de Sobrevida
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
3Z8479ZZ5X (Epirubicin); 80168379AG (Doxorubicin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180207
[Lr] Data última revisão:
180207
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180129
[St] Status:MEDLINE


  4 / 4840 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29240363
[Au] Autor:Gezginci E; Yyigun E; Yalcin S; Ozgok IY
[Ti] Título:Symptoms Control for Patients with Superficial Bladder Cancers Before and After TURBT and Intravesical Epirubicin Instillation.
[So] Source:Urol Nurs;37(1):31-5, 2017 Jan-Feb.
[Is] ISSN:1053-816X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Bladder cancer is one of the most common cancers among urologic cancers. Intravesical instillation following transurethral resection of bladder tumor (TURBT) is used as a treatment of bladder cancer. According to results of this study, before and after intravesical instillations following TURBT have no effect on symptom outcomes of patients with superficial bladder cancer.
[Mh] Termos MeSH primário: Antibióticos Antineoplásicos/administração & dosagem
Carcinoma de Células de Transição/terapia
Cistoscopia/métodos
Epirubicina/administração & dosagem
Neoplasias da Bexiga Urinária/terapia
[Mh] Termos MeSH secundário: Administração Intravesical
Adolescente
Adulto
Idoso
Ansiedade/epidemiologia
Carcinoma de Células de Transição/epidemiologia
Carcinoma de Células de Transição/patologia
Depressão/epidemiologia
Fadiga/epidemiologia
Feminino
Seres Humanos
Masculino
Meia-Idade
Náusea/epidemiologia
Invasividade Neoplásica
Dor Pós-Operatória/epidemiologia
Período Pós-Operatório
Avaliação de Sintomas
Turquia/epidemiologia
Neoplasias da Bexiga Urinária/epidemiologia
Neoplasias da Bexiga Urinária/patologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibiotics, Antineoplastic); 3Z8479ZZ5X (Epirubicin)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180123
[Lr] Data última revisão:
180123
[Sb] Subgrupo de revista:N
[Da] Data de entrada para processamento:171215
[St] Status:MEDLINE


  5 / 4840 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28832225
[Au] Autor:Hanafi-Bojd MY; Moosavian Kalat SA; Taghdisi SM; Ansari L; Abnous K; Malaekeh-Nikouei B
[Ad] Endereço:a Cellular and Molecular Research Center, Department of Pharmacology, School of Medicine , Birjand University of Medical Sciences , Birjand , Iran.
[Ti] Título:MUC1 aptamer-conjugated mesoporous silica nanoparticles effectively target breast cancer cells.
[So] Source:Drug Dev Ind Pharm;44(1):13-18, 2018 Jan.
[Is] ISSN:1520-5762
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:In the present study, we developed aptamer (Apt) conjugated mesoporous silica nanoparticles (MSNs) for specific delivery of epirubicin (EPI) to breast cancer cells. MSNs were synthesized and functionalized with 3-mercaptopropyltrimethoxysilane (3-MPTMS), followed by MUC1 aptamer conjugation through disulfide bonds. The nanoparticles were analyzed by transmission electron microscopy (TEM), particle size analyzer, zeta potential, elemental analysis (CHNS), aptamer conjugation efficiency, drug loading efficiency, and drug release profile. Cell uptake and in vitro cytotoxicity of different formulations were performed. The results of MSNs characterization confirmed spherical nanoparticles with thiol functional groups. Particle size of obtained nanoparticles was 163 nm in deionized water. After conjugation of MUC1 aptamer and EPI loading (MSN-MUC1-EPI), particle size increased to 258 nm. The aptamer conjugation to MSNs with disulfide bonds were confirmed using gel retardation assay. Cellular uptake studies revealed better cell uptake of MSN-MUC1-EPI compared to MSN-EPI. Moreover, cytotoxicity study results in MCF7 cell lines showed improved cytotoxicity of MSN-MUC1-EPI in comparison with MSN-EPI or EPI at the same concentration of drug. These results exhibited that MSN-MUC1-EPI has the potential for targeted drug delivery into MUC1 positive breast cancer cells to improve drug efficacy and alleviate side effects.
[Mh] Termos MeSH primário: Neoplasias da Mama/química
Sistemas de Liberação de Medicamentos/métodos
Epirubicina/farmacocinética
Nanopartículas/química
Silanos/farmacocinética
Dióxido de Silício/química
[Mh] Termos MeSH secundário: Neoplasias da Mama/metabolismo
Linhagem Celular Tumoral
Liberação Controlada de Fármacos
Epirubicina/química
Seres Humanos
Células MCF-7
Tamanho da Partícula
Silanos/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Silanes); 3Z8479ZZ5X (Epirubicin); 7631-86-9 (Silicon Dioxide); 8CB1M08OIW ((3-mercaptopropyl)trimethoxysilane)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180111
[Lr] Data última revisão:
180111
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170824
[St] Status:MEDLINE
[do] DOI:10.1080/03639045.2017.1371734


  6 / 4840 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29277779
[Au] Autor:Kishimoto S; Aoki H; Suzuki R; Inoue M; Fukushima S
[Ad] Endereço:Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Kobe, Japan skisimot@pharm.kobegakuin.ac.jp.
[Ti] Título:Angiographic Evaluation of Vascular Damage in Rat Liver After Administration of Epirubicin or Miriplatin.
[So] Source:Anticancer Res;38(1):247-251, 2018 01.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Maintaining the function of blood vessels is important for the control of hepatocellular carcinoma (HCC) during treatment with repeated transcatheter arterial chemoembolization (TACE). This study was designed to compare the vascular damage caused by miriplatin (MPT), which has been commonly used for TACE, with the damage caused by epirubicin (EPI). MATERIALS AND METHODS: We used the portal vein of healthy rats for the administration of the drug (MPT or EPI) and/or soybean oil as vehicle. After 2 days, angiography was performed by X-ray computer tomography. RESULTS: The influence of soybean oil on blood vessel function was volume-dependent. EPI showed dose-dependent effects on angiography, and 0.5 mg EPI led to severe (grade 4) blood flow disturbance in all animals. The effect of 1 mg MPT on blood vessels was mild (grade 1) in all animals and not different from that of soybean oil alone. CONCLUSION: Less vascular damage is caused by MPT than by EPI, suggesting that MPT is a useful drug for TACE in HCC.
[Mh] Termos MeSH primário: Antineoplásicos/efeitos adversos
Epirubicina/efeitos adversos
Fígado/efeitos dos fármacos
Compostos Organoplatínicos/efeitos adversos
[Mh] Termos MeSH secundário: Angiografia
Animais
Antineoplásicos/administração & dosagem
Sulfato de Bário/farmacologia
Quimioembolização Terapêutica
Epirubicina/administração & dosagem
Feminino
Seres Humanos
Fígado/irrigação sanguínea
Fígado/diagnóstico por imagem
Compostos Organoplatínicos/administração & dosagem
Ratos Sprague-Dawley
Óleo de Soja/administração & dosagem
Tomografia Computadorizada por Raios X
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Organoplatinum Compounds); 25BB7EKE2E (Barium Sulfate); 3Z8479ZZ5X (Epirubicin); 780F0P8N4I (miriplatin); 8001-22-7 (Soybean Oil)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180105
[Lr] Data última revisão:
180105
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171227
[St] Status:MEDLINE


  7 / 4840 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29180210
[Au] Autor:Ishikawa T; Akazawa K; Hasegawa Y; Tanino H; Horiguchi J; Miura D; Hayashi M; Kohno N
[Ad] Endereço:Department of Breast Surgery and Oncology, Tokyo Medical University, Tokyo, Japan. Electronic address: tishik55@gmail.com.
[Ti] Título:Survival outcomes of neoadjuvant chemotherapy with zoledronic acid for HER2-negative breast cancer.
[So] Source:J Surg Res;220:46-51, 2017 Dec.
[Is] ISSN:1095-8673
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: A randomized phase 2 trial in women with HER2-negative breast cancer has shown that adding zoledronic acid (ZOL) to neoadjuvant chemotherapy (CT) has potential anticancer benefits in postmenopausal and triple-negative (TN) breast cancer patients. We report the data for the secondary end point of disease-free survival (DFS). METHODS: Patients were randomly assigned to receive CT or CT + ZOL (CT-Z). All patients received four cycles of FEC100 followed by 12 cycles of paclitaxel weekly. ZOL (4 mg) was administered 3-4 times weekly for 7 wk to the CT-Z group patients. The primary end point was pathologic complete response (pCR). The secondary end points were the clinical response rates, rate of breast-conserving surgery, safety, and DFS. RESULTS: Of the 188 patients enrolled, 95 were assigned to the CT group and 93 to the CT-Z group. DFS and overall survival were analyzed in 92 and 88 patients with the mean times of 5.15 y and 5.38 y, respectively. The 3-y DFS rate was 84.6% in the CT group and 90.8% in the CT-Z group (P = 0.188). The particular benefit from ZOL for the neoadjuvant CT seen as improvement of the pCR rate was indicated in the 3-y DFS period for TN cancer cases (CT versus CT-Z: 70.6% versus 94.1%) but not for postmenopausal cases. CONCLUSIONS: ZOL did not improve DFS when combined with CT. However, the improvement of the pCR rate translated to survival outcomes in TN breast cancer. The short-term application of ZOL may not be sufficient to improve the outcome in postmenopausal patients.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Neoplasias da Mama/tratamento farmacológico
Neoplasias da Mama/mortalidade
Difosfonatos/uso terapêutico
Imidazóis/uso terapêutico
Terapia Neoadjuvante/métodos
[Mh] Termos MeSH secundário: Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
Neoplasias da Mama/patologia
Neoplasias da Mama/cirurgia
Ciclofosfamida/efeitos adversos
Ciclofosfamida/uso terapêutico
Difosfonatos/efeitos adversos
Intervalo Livre de Doença
Epirubicina/efeitos adversos
Epirubicina/uso terapêutico
Feminino
Fluoruracila/efeitos adversos
Fluoruracila/uso terapêutico
Seguimentos
Seres Humanos
Imidazóis/efeitos adversos
Mastectomia Segmentar
Terapia Neoadjuvante/efeitos adversos
Paclitaxel/efeitos adversos
Paclitaxel/uso terapêutico
Pós-Menopausa
Receptor ErbB-2/metabolismo
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Diphosphonates); 0 (Imidazoles); 3Z8479ZZ5X (Epirubicin); 6XC1PAD3KF (zoledronic acid); 8N3DW7272P (Cyclophosphamide); EC 2.7.10.1 (ERBB2 protein, human); EC 2.7.10.1 (Receptor, ErbB-2); P88XT4IS4D (Paclitaxel); U3P01618RT (Fluorouracil)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171211
[Lr] Data última revisão:
171211
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171129
[St] Status:MEDLINE


  8 / 4840 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29061821
[Au] Autor:Mazur L; Opydo-Chanek M; Sladowska K; Janota B; Klaput U; Lukawska M; Oszczapowicz I
[Ad] Endereço:Department of Experimental Hematology, Institute of Zoology and Biomedical Research, Jagiellonian University, Krakow, Poland lidia.mazur@uj.edu.pl.
[Ti] Título: Antileukemic Activity of Formamidine Epidoxorubicin Analogs.
[So] Source:Anticancer Res;37(11):6363-6372, 2017 11.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIM: Epidoxorubicin is an anthracycline agent. The present study was undertaken to compare the antileukemic potential of epidoxorubicin and its two formamidine analogs containing either a morpholine moiety (EPIFmor) or a hexamethyleneimine moiety (EPIFhex) in the amidine group. MATERIALS AND METHODS: The experiments were performed in vitro on MOLT-4 cells using spectrophotometry, Coulter electrical impedance, flow cytometry, and light microscopy methods. RESULTS: The leukemia cell responses to the action of the anthracyclines were manifested in their different viability, count and volume, degree of apoptosis and necrosis, activity of caspases -8, -9, and -3/7, mitochondrial membrane potential, and in the cell-cycle distribution. In general, epidoxorubicin appeared to be the most active, and EPIFmor was more active than EPIFhex against MOLT-4 cells. CONCLUSION: The structural modifications of epidoxorubicin in the amidine group were responsible for the varied action of its formamidine analogs on human acute lymphoblastic leukemia cells.
[Mh] Termos MeSH primário: Amidinas/farmacologia
Antraciclinas/farmacologia
Antineoplásicos/farmacologia
Caspases/metabolismo
Leucemia-Linfoma Linfoblástico de Células Precursoras/metabolismo
[Mh] Termos MeSH secundário: Amidinas/química
Antraciclinas/química
Antineoplásicos/química
Apoptose
Ciclo Celular/efeitos dos fármacos
Linhagem Celular Tumoral
Sobrevivência Celular/efeitos dos fármacos
Epirubicina/análogos & derivados
Seres Humanos
Técnicas In Vitro
Potenciais da Membrana/efeitos dos fármacos
Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Amidines); 0 (Anthracyclines); 0 (Antineoplastic Agents); 3Z8479ZZ5X (Epirubicin); EC 3.4.22.- (Caspases)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171026
[Lr] Data última revisão:
171026
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171025
[St] Status:MEDLINE


  9 / 4840 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29019894
[Au] Autor:Lu Y; Huang H; Yang H; Chen D
[Ad] Endereço:Department of Oncology, Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Gaungxi, China.
[Ti] Título:Randomized controlled trial of late-course concurrent versus sequential chemoradiotherapy after mastectomy and axillary surgery in locally advanced breast cancer.
[So] Source:Medicine (Baltimore);96(41):e8252, 2017 Oct.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Concurrent chemoradiotherapy could increase the local control rate in patients with high recurrence risk after breast-conserving surgery, but the effect of concurrent chemoradiotherapy after mastectomy and axillary dissection is not clear. The aim of the study was to compare the effects of late-course concurrent chemoradiotherapy (CCRT) versus sequential therapy (SCRT) after mastectomy and axillary surgery in locally advanced breast cancer. METHODS: This was a randomized controlled trial of 155 patients with stage pT3-4p N1-3c M0 or pAnyT pN2-3c M0 breast cancer undergoing 5-fluorouracil+epirubicin+cyclophosphamide followed by docetaxel (FEC-D) chemotherapy after mastectomy and axillary dissection. Patients were randomized to the CCRT group (intensity-modulated radiation therapy was performed concurrently with docetaxel) or to the SCRT group (radiotherapy after chemotherapy). Recurrences, adverse reactions, and short-term effects were observed. RESULTS: All the patients completed the planned therapy. The median follow-up was 39 (range, 16-62) months. Compared with SCRT, the 3-year local-regional recurrence-free survival (LRFS) in the CCRT group was improved (81.8% vs 92.3%, P = .046). There was no significant difference in 3-year disease-free survival (DFS) and overall survival (OS). In the pT3-4 pN1-3 cM0 subgroup, the 3-year local recurrence-free survival and DFS were significantly improved in the CCRT group (69.4% vs 88.2%, P = .036; and 41.7% vs 72.6%, P = .049, respectively). No significant difference was observed adverse reactions between the 2 groups. CONCLUSION: LRFS of patients with locally advanced invasive breast cancer after mastectomy and axillary surgery was better with CCRT than with SCRT and with similar profiles of adverse reactions. The DFS of patients staged pT3-4 pN1-3 cM0 was also improved.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica
Neoplasias da Mama
Excisão de Linfonodo/métodos
Linfonodos
Mastectomia/métodos
Taxoides
[Mh] Termos MeSH secundário: Adulto
Antineoplásicos/administração & dosagem
Antineoplásicos/efeitos adversos
Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
Axila
Neoplasias da Mama/patologia
Neoplasias da Mama/terapia
Quimiorradioterapia
Ciclofosfamida/administração & dosagem
Ciclofosfamida/efeitos adversos
Fracionamento de Dose
Esquema de Medicação
Epirubicina/administração & dosagem
Epirubicina/efeitos adversos
Feminino
Fluoruracila/administração & dosagem
Fluoruracila/efeitos adversos
Seres Humanos
Linfonodos/patologia
Linfonodos/cirurgia
Meia-Idade
Invasividade Neoplásica
Estadiamento de Neoplasias
Taxoides/administração & dosagem
Taxoides/efeitos adversos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Taxoids); 15H5577CQD (docetaxel); 3Z8479ZZ5X (Epirubicin); 8N3DW7272P (Cyclophosphamide); U3P01618RT (Fluorouracil)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171122
[Lr] Data última revisão:
171122
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171012
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008252


  10 / 4840 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28976791
[Au] Autor:Fuchs CS; Niedzwiecki D; Mamon HJ; Tepper JE; Ye X; Swanson RS; Enzinger PC; Haller DG; Dragovich T; Alberts SR; Bjarnason GA; Willett CG; Gunderson LL; Goldberg RM; Venook AP; Ilson D; O'Reilly E; Ciombor K; Berg DJ; Meyerhardt J; Mayer RJ
[Ad] Endereço:Charles S. Fuchs, Yale Cancer Center, Smilow Cancer Hospital, New Haven, CT; Charles S. Fuchs, Peter C. Enzinger, Jeffrey Meyerhardt, and Robert J. Mayer, Dana-Farber/Partners CancerCare; Harvey J. Mamon and Richard S. Swanson, Brigham and Women's Hospital, Boston, MA; Donna Niedzwiecki and Xing Ye,
[Ti] Título:Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance).
[So] Source:J Clin Oncol;35(32):3671-3677, 2017 Nov 10.
[Is] ISSN:1527-7755
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Purpose After curative resection of gastric or gastroesophageal junction adenocarcinoma, Intergroup Trial 0116 (Phase III trial of postoperative adjuvant radiochemotherapy for high risk gastric and gastroesophageal junction adenocarcinoma: Demonstrated superior survival for patients who received postoperative chemoradiotherapy with bolus fluorouracil (FU) and leucovorin (LV) compared with surgery alone. CALGB 80101 (Alliance; Phase III Intergroup Trial of Adjuvant Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma) assessed whether a postoperative chemoradiotherapy regimen that replaced FU plus LV with a potentially more active systemic therapy could further improve overall survival. Patients and Methods Between April 2002 and May 2009, 546 patients who had undergone a curative resection of stage IB through IV (M0) gastric or gastroesophageal junction adenocarcinoma were randomly assigned to receive either postoperative FU plus LV before and after combined FU and radiotherapy (FU plus LV arm) or postoperative epirubicin, cisplatin, and infusional FU (ECF) before and after combined FU and radiotherapy (ECF arm). Results With a median follow-up duration of 6.5 years, 5-year overall survival rates were 44% in the FU plus LV arm and 44% in the ECF arm ( P = .69; multivariable hazard ratio, 0.98; 95% CI, 0.78 to 1.24 comparing ECF with FU plus LV). Five-year disease-free survival rates were 39% in the FU plus LV arm and 37% in the ECF arm ( P = .94; multivariable hazard ratio, 0.96; 95% CI, 0.77 to 1.20). In post hoc analyses, the effect of treatment seemed to be similar across all examined patient subgroups. Conclusion After a curative resection of gastric or gastroesophageal junction adenocarcinoma, postoperative chemoradiotherapy using a multiagent regimen of ECF before and after radiotherapy does not improve survival compared with standard FU and LV before and after radiotherapy.
[Mh] Termos MeSH primário: Adenocarcinoma/terapia
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Quimiorradioterapia Adjuvante
Junção Esofagogástrica
Neoplasias Gástricas/terapia
[Mh] Termos MeSH secundário: Adenocarcinoma/patologia
Adulto
Idoso
Idoso de 80 Anos ou mais
Cisplatino/administração & dosagem
Terapia Combinada
Epirubicina/administração & dosagem
Feminino
Fluoruracila/administração & dosagem
Seres Humanos
Leucovorina/administração & dosagem
Masculino
Meia-Idade
Recidiva Local de Neoplasia
Estadiamento de Neoplasias
Fatores de Risco
Neoplasias Gástricas/patologia
Taxa de Sobrevida
Resultado do Tratamento
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
3Z8479ZZ5X (Epirubicin); Q20Q21Q62J (Cisplatin); Q573I9DVLP (Leucovorin); U3P01618RT (Fluorouracil)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171126
[Lr] Data última revisão:
171126
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171005
[St] Status:MEDLINE
[do] DOI:10.1200/JCO.2017.74.2130



página 1 de 484 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde